ZFGN - Zafgen, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
8.02
+0.25 (+3.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.77
Open7.85
Bid7.10 x 100
Ask10.00 x 500
Day's Range7.73 - 8.12
52 Week Range3.21 - 9.36
Volume131,325
Avg. Volume177,665
Market Cap220.466M
Beta-0.58
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateMar 7, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.67
Trade prices are not sourced from all markets
  • GlobeNewswire17 days ago

    Zafgen to Present at the Leerink Partners 7th Annual Global Healthcare Conference

    BOSTON, Feb. 08, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • ACCESSWIRE2 months ago

    Blog Exposure - Zafgen Reports Strong Clinical Progress and Updates Outlook

    LONDON, UK / ACCESSWIRE / January 08, 2018 / Active-Investors.com has just released a free research report on Zafgen Inc. (NASDAQ: ZFGN ). If you want access to this report all you need to do is sign up ...

  • GlobeNewswire2 months ago

    Zafgen Reports Strong Clinical Progress and Updates Outlook for 2018  

    ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year. Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as first indication. ...

  • Marketwired4 months ago

    Zafgen Reports Third Quarter 2017 Financial Results

    Zafgen, Inc. , a clinical-stage biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by type 2 diabetes, rare diseases and other metabolic diseases, ...

  • When Will Zafgen Inc (ZFGN) Run Out Of Cash?
    Simply Wall St.5 months ago

    When Will Zafgen Inc (ZFGN) Run Out Of Cash?

    As the USD $96.19M market cap Zafgen Inc (NASDAQ:ZFGN) released another year of negative earnings, investors may be on edge waiting for breakeven. Cash is crucial to run a business,Read More...

  • Associated Press7 months ago

    Zafgen reports 2Q loss

    The Boston-based company said it had a loss of 49 cents per share. The company's shares closed at $3.41. A year ago, they were trading at $3.21. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...

  • ACCESSWIRE7 months ago

    Investor Network: Zafgen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Zafgen, Inc. (NASDAQ: ZFGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. ...

  • Associated Press10 months ago

    Zafgen reports 1Q loss

    The Boston-based company said it had a loss of 48 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • TheStreet.com10 months ago

    Zafgen Rebounds With a Safer Obesity Drug Targeting Diabetics

    Zafgen is disclosing Thursday evening the first human data on ZGN-1061, with plans to move the obesity drug into a phase II study.

  • Thomson Reuters StreetEvents10 months ago

    Edited Transcript of ZFGN earnings conference call or presentation 9-Mar-17 9:30pm GMT

    Q4 2016 Zafgen Inc Earnings Call

  • Associated Presslast year

    Zafgen reports 4Q loss

    The Boston-based company said it had a loss of 38 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...